Last updated: September 3, 2026
The chlorpheniramine maleate, hydrocodone bitartrate, and pseudoephedrine hydrochloride combination is a prescription oral solution marketed in the United States under the Zutripro brand. Its commercial position is weak: the product competes in a declining opioid cough market, faces controlled-substance dispensing restrictions, has limited differentiation from older hydrocodone cough medicines, and lacks publicly reported product-level revenue.
The combination contains:
- Hydrocodone bitartrate, an opioid antitussive
- Chlorpheniramine maleate, a first-generation antihistamine
- Pseudoephedrine hydrochloride, a nasal decongestant
FDA labeling identifies the product as an oral solution containing 5 mg hydrocodone bitartrate, 4 mg chlorpheniramine maleate, and 15 mg pseudoephedrine hydrochloride per 5 mL. It is indicated for temporary relief of cough, upper respiratory symptoms, and nasal congestion associated with allergy or the common cold in adults and appropriate pediatric patients under the labeling restrictions in effect at approval. [1]
What drug is chlorpheniramine, hydrocodone, and pseudoephedrine?
The combination is a multi-symptom prescription cough and cold product. Its therapeutic rationale is straightforward: hydrocodone suppresses cough, chlorpheniramine reduces histamine-mediated symptoms, and pseudoephedrine reduces nasal congestion through vasoconstriction.
| Attribute |
Product detail |
| Active ingredients |
Hydrocodone bitartrate, chlorpheniramine maleate, pseudoephedrine hydrochloride |
| Dosage form |
Oral solution |
| Common U.S. brand |
Zutripro |
| Hydrocodone strength |
5 mg per 5 mL |
| Chlorpheniramine strength |
4 mg per 5 mL |
| Pseudoephedrine strength |
15 mg per 5 mL |
| Regulatory class |
Prescription controlled substance |
| Opioid schedule |
Schedule II |
| Primary market |
U.S. prescription cough and cold |
| Main competitors |
Tussionex, Vituz, hydrocodone-homatropine, codeine cough products, non-opioid cough products |
The product’s commercial value depends on the hydrocodone component. Chlorpheniramine and pseudoephedrine are widely available in other products, including non-opioid and over-the-counter formulations. Those ingredients therefore provide limited exclusivity or pricing leverage.
What is the FDA regulatory status of Zutripro?
Zutripro was approved through an FDA new drug application for a prescription oral solution. Hydrocodone-containing cough medicines are subject to Schedule II controls, prescription monitoring, controlled-substance ordering requirements, and heightened scrutiny of prescribing and dispensing practices. The FDA reclassified hydrocodone combination products from Schedule III to Schedule II in 2014. [2]
The regulatory profile creates several market constraints:
- Pharmacies must manage Schedule II inventory, ordering, recordkeeping, and dispensing controls.
- Schedule II prescriptions generally cannot be refilled.
- State opioid prescribing rules can impose restrictions beyond federal requirements.
- Prescribers increasingly favor non-opioid treatments for routine cough and cold symptoms.
- Pediatric use is constrained by FDA safety actions affecting opioid-containing cough and cold products.
FDA required labeling changes for prescription opioid cough and cold medicines in 2018, limiting their use in pediatric patients younger than 18 because of risks including respiratory depression, misuse, addiction, overdose, and death. [3] The action reduced the addressable pediatric market and weakened the clinical rationale for opioid cough products in primary-care settings.
When does this product lose exclusivity?
The principal commercial exclusivity period for an older combination product has expired. FDA approval occurred in the late 2000s or early 2010s, placing any standard three-year clinical investigation exclusivity well behind the product. Five-year new chemical entity exclusivity would not generally apply to a combination of previously known active ingredients unless the application satisfied the statutory requirements for a new chemical entity, which this product did not.
Publicly available product information does not establish a durable, currently meaningful patent barrier around the combination. The active ingredients are longstanding generic compounds, and the dosage form is a conventional oral solution rather than a technically complex delivery system.
| Exclusivity category |
Commercial status |
| New chemical entity exclusivity |
Not a practical current barrier |
| Three-year clinical investigation exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No current market-relevant barrier identified |
| Formulation patent protection |
No publicly established blocking estate identified |
| Method-of-use patent protection |
No material current barrier identified |
| Regulatory exclusivity |
Expired or commercially immaterial |
The absence of a significant patent moat means that market access depends more on FDA approval, manufacturing capability, controlled-substance compliance, wholesaler access, and pharmacy demand than on intellectual-property protection.
What is the Orange Book status of the combination?
The relevant FDA regulatory asset is the approved prescription product and its associated NDA listing. An Orange Book listing, where active, establishes the reference product for abbreviated new drug application purposes. It does not guarantee meaningful commercial protection when the listed drug has limited demand or when no blocking patents remain.
For this combination, the key Orange Book implications are:
- The product is a drug reference point for potential generic oral solutions.
- Any listed patents would need to be evaluated for expiration, delisting, and enforceability.
- A generic applicant could use an ANDA if it can match the reference product’s active ingredients, strength, dosage form, route, and relevant quality attributes.
- Controlled-substance scheduling does not prevent ANDA competition, but it raises manufacturing, distribution, quota, and compliance requirements.
An applicant challenging a listed patent could submit a Paragraph IV certification. Public sources do not establish a significant, continuing Paragraph IV litigation campaign surrounding this combination. That absence is consistent with the product’s limited commercial scale and relatively weak patent differentiation.
How strong is the patent estate for hydrocodone, chlorpheniramine, and pseudoephedrine?
The patent estate appears weak from a commercial defense perspective.
Active ingredients
Hydrocodone, chlorpheniramine, and pseudoephedrine are mature compounds with extensive prior art. Composition-of-matter exclusivity is unavailable for a conventional combination of these known ingredients.
Formulation protection
An oral solution can theoretically be protected through patents covering:
- Solubility enhancement
- Taste masking
- Preservative systems
- Stability
- Dosing accuracy
- Abuse-deterrent characteristics
- Manufacturing processes
No widely recognized, high-value formulation barrier has emerged as a defining feature of this product. The product is not generally identified with an extended-release platform, abuse-deterrent technology, device-based delivery system, or biologic manufacturing process.
Method-of-use protection
The product’s use for cough, upper respiratory symptoms, and congestion is conventional. Broad method-of-use claims would face substantial prior-art and obviousness risks. A narrow method claim could exist, but it would have limited ability to protect the overall market.
Manufacturing barriers
Manufacturing is more difficult than producing a standard non-controlled oral liquid because hydrocodone requires controlled-substance security, inventory reconciliation, quota management, and specialized distribution controls. Those requirements create operational barriers but do not create durable patent exclusivity.
What market dynamics affect the product?
The market is structurally unfavorable for opioid cough combinations.
Opioid safety restrictions
Hydrocodone products face prescribing limits, state-level opioid regulations, prescription drug monitoring, and heightened pharmacy review. The 2014 Schedule II reclassification increased friction across the prescribing and dispensing chain. [2]
Substitution by non-opioid products
Patients and clinicians can substitute:
- Dextromethorphan products
- Benzonatate
- Guaifenesin combinations
- Antihistamine-decongestant products
- Intranasal corticosteroids
- Saline and other supportive therapies
These substitutes usually have lower regulatory friction and broader retail availability.
Pediatric contraction
FDA restrictions on opioid cough and cold products for patients younger than 18 removed or reduced an important historical use segment. [3]
Pseudoephedrine controls
Pseudoephedrine sales are subject to federal purchase limits, identification requirements, sales logs, and state controls under the Combat Methamphetamine Epidemic Act. [4] These restrictions affect product availability and pharmacy workflows even when the drug is dispensed by prescription.
Limited clinical differentiation
The combination places three established ingredients into one liquid dosage form. That convenience has value, but it does not create strong clinical differentiation from separate products or other fixed-dose cough formulations.
What is the financial trajectory of the product?
No public filing provides reliable, standalone revenue, gross margin, prescription volume, or cash-flow data for the chlorpheniramine-hydrocodone-pseudoephedrine combination. The product is not separately reported as a material revenue segment by a large public pharmaceutical company.
The likely financial trajectory is:
| Period |
Market condition |
Financial effect |
| Launch and early commercialization |
Differentiated prescription combination with limited direct competition |
Initial opportunity for branded pricing |
| Generic and mature-product phase |
Established ingredients and limited patent protection |
Price pressure and lower prescriber loyalty |
| Post-2014 opioid-control phase |
Schedule II restrictions and compliance costs |
Lower volume and higher commercial friction |
| Post-2018 pediatric-label phase |
Reduced pediatric addressable market |
Further demand contraction |
| Current mature phase |
Substitution by non-opioid products and uncertain availability |
Low strategic value absent a differentiated formulation |
Revenue exposure is likely concentrated in a small number of prescriptions and seasonal demand periods. Unlike a chronic therapy, the product does not generate recurring treatment revenue from a stable diagnosed population. Demand depends on acute respiratory illness, allergy seasons, prescriber habits, pharmacy stocking, and payer coverage.
The product also lacks the economic characteristics that attract large-scale specialty pharmaceutical investment:
- No durable biologic exclusivity
- No specialty distribution premium
- No high-value chronic indication
- No major device or delivery platform
- No clear indication expansion pathway
- No strong patent-backed pricing power
A smaller manufacturer could still find value in niche supply, contract manufacturing, or portfolio bundling. The economic case would depend on manufacturing efficiency and reliable controlled-substance distribution rather than on brand expansion.
Which companies compete with this product?
Competition comes from both opioid and non-opioid products.
| Competitive group |
Examples |
Competitive effect |
| Hydrocodone-antihistamine liquids |
Tussionex, Vituz and related products |
Direct therapeutic substitution |
| Hydrocodone antitussives |
Hydrocodone-homatropine products |
Cough suppression without pseudoephedrine |
| Codeine products |
Codeine-guaifenesin and related products |
Lower-cost opioid alternatives, subject to safety limits |
| Non-opioid antitussives |
Dextromethorphan, benzonatate |
Lower regulatory and prescribing friction |
| Decongestant combinations |
Pseudoephedrine and phenylephrine products |
Substitution for congestion relief |
| Expectorant products |
Guaifenesin combinations |
Alternative symptom management |
Tussionex has a stronger historical brand position in hydrocodone-antihistamine cough treatment, while non-opioid products have a broader retail and payer footprint. The three-ingredient combination therefore occupies a narrow segment between branded opioid cough products and inexpensive OTC therapies.
What generic launch risks exist?
The main generic risk is not a sudden high-value patent cliff. It is gradual erosion through approved competing products, therapeutic substitution, and declining branded demand.
A potential generic entrant would need to address:
- Same active ingredients and strengths
- Oral-solution sameness
- Taste and palatability
- Stability and preservative performance
- Controlled-substance manufacturing and distribution
- FDA ANDA requirements
- State and federal opioid compliance
- Pseudoephedrine sales controls
- Pharmacy and wholesaler acceptance
The commercial return may be insufficient for multiple generic manufacturers. Controlled-substance obligations can reduce the number of willing entrants, but they also raise the product’s cost base. A first generic could obtain temporary market share without generating large absolute revenue because the total market is limited.
What litigation and settlement agreements affect the product?
No major continuing patent litigation or widely reported Paragraph IV settlement is established for this combination in the cited public sources. The principal legal risk is regulatory and compliance-related rather than patent litigation.
Relevant risk areas include:
- Controlled-substance distribution compliance
- Opioid marketing and prescribing practices
- Product liability involving respiratory depression or misuse
- Failure-to-warn claims
- Manufacturing deviations
- Diversion and suspicious-order monitoring
- State opioid enforcement
The absence of prominent patent litigation reduces legal uncertainty for generic entry, but it also confirms that intellectual property is not the primary commercial asset.
How does this product compare with Tussionex and non-opioid cough medicines?
| Factor |
Chlorpheniramine/hydrocodone/pseudoephedrine |
Tussionex |
Non-opioid cough products |
| Opioid present |
Yes |
Yes |
Usually no |
| Pseudoephedrine present |
Yes |
No |
Sometimes |
| Controlled substance |
Schedule II |
Schedule II |
Usually not controlled |
| Pediatric market |
Restricted |
Restricted |
Broader, product-dependent |
| Patent strength |
Limited current protection identified |
Brand and formulation history may be stronger |
Varies by product |
| Pharmacy friction |
High |
High |
Low to moderate |
| Generic exposure |
High |
High |
High |
| Clinical differentiation |
Multi-symptom convenience |
Long-acting hydrocodone-antihistamine positioning |
Often lower efficacy for severe cough but easier access |
| Revenue outlook |
Declining or niche |
Mature and pressured |
Larger, broader consumer market |
Key Takeaways
- The combination is a mature prescription opioid cough product sold historically under the Zutripro brand.
- Its active ingredients are established compounds with limited composition-of-matter protection.
- FDA and state opioid controls materially restrict prescribing, dispensing, and pediatric use.
- The product has no publicly established high-value patent estate that would support long-term exclusivity.
- Public filings do not provide reliable standalone revenue or profit data.
- Financial performance is likely declining or niche, with demand concentrated in acute respiratory and allergy seasons.
- Non-opioid cough medicines and separate decongestant or antihistamine products are the primary commercial substitutes.
- Generic entry risk is technically manageable but economically limited by controlled-substance compliance and a small addressable market.
- The main barriers are regulatory, manufacturing, and distribution-related rather than patent-based.
FAQs
Is chlorpheniramine-hydrocodone-pseudoephedrine still commercially important?
No. It is a mature, narrow-market prescription product with declining demand relative to non-opioid cough medicines and lower-risk symptom treatments.
Is Zutripro a Schedule II drug?
Yes. The hydrocodone component makes the product subject to Schedule II controlled-substance requirements following the FDA and DEA reclassification of hydrocodone combination products.
Can a generic manufacturer launch this three-ingredient oral solution?
Yes, subject to FDA approval, controlled-substance compliance, manufacturing controls, and the absence of enforceable blocking patents. The commercial opportunity may be limited by low market volume.
Does pseudoephedrine create a separate patent barrier?
No. Pseudoephedrine creates regulatory and pharmacy-handling requirements, including sales controls and recordkeeping, but it does not provide meaningful patent exclusivity for this combination.
Is biosimilar competition relevant to this product?
No. Biosimilars apply to biologic products. This combination is a conventional small-molecule oral solution and would face generic, not biosimilar, competition.
References
- U.S. Food and Drug Administration. (2010). Zutripro prescribing information. FDA Drugs@FDA.
- U.S. Drug Enforcement Administration. (2014). Schedules of controlled substances: Placement of hydrocodone combination products into Schedule II. 79 Fed. Reg. 49661.
- U.S. Food and Drug Administration. (2018). FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older.
- U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005, Title VII of the USA PATRIOT Improvement and Reauthorization Act.
